ArticleBrain pathology (Zurich, Switzerland)2011
Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas.
Article in Brain pathology (Zurich, Switzerland), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Molecular features in gangliogliomas: a systematic review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Pooled it
- Multicenter evaluation of the Idylla IDH1-2 Mutation Assay Kit for detection of IDH mutational status in glioma.Virchows Archiv : an international journal of pathology · 2026Article
- Thalamic Ganglioglioma Treated With Radical Radiotherapy: A Rare Location and an Exclusive Form of Treatment.Cureus · 2024Article
- Altered Extracellular Matrix as an Alternative Risk Factor for Epileptogenicity in Brain Tumors.Biomedicines · 2022Review
- Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours.Nature reviews. Neurology · 2022Review
- Low-grade epilepsy-associated neuroepithelial tumors: Tumor spectrum and diagnosis based on genetic alterations.Frontiers in neuroscience · 2022Review
- Anaplastic ganglioglioma originating from the medulla oblongata: case report.Translational cancer research · 2021Article
- The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.Neuro-oncology · 2019Review
- Suprasellar ganglioglioma presenting as a middle cerebral artery infarction.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2019Article
- Pathologic and molecular aspects of anaplasia in circumscribed gliomas and glioneuronal tumors.Brain tumor pathology · 2019Review
- Prolonged Response Induced by Single Agent Vemurafenib in aFrontiers in oncology · 2019Article
- VHA Practice Guideline Recommendations for Diffuse Gliomas.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2018Article
- H3 K27M Mutation in Gangliogliomas can be Associated with Poor Prognosis.Brain pathology (Zurich, Switzerland) · 2017Article
- Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomas.Brain pathology (Zurich, Switzerland) · 2017Article
- Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors.Neuro-oncology · 2016Article
- 2-Hydoxyglutarate: D/Riving Pathology in gLiomaS.Brain pathology (Zurich, Switzerland) · 2015Review
- The evolving molecular genetics of low-grade glioma.Advances in anatomic pathology · 2015Review
- Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.CNS oncology · 2015Review
- New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.International journal of medical sciences · 2015Review
- Pathology and genetics of diffuse gliomas in adults.Neurologia medico-chirurgica · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
Recent work has identified novel point mutations in isocitrate dehydrogenase 1 (IDH1) in the majority of the World Health Organization grades II and III infiltrative gliomas and secondary grade IV glioblastomas. Gangliogliomas consist of neoplastic ganglion and glial cells and, in contrast to infiltrative gliomas, are generally indolent. Yet distinguishing between a ganglioglioma and an infiltrative glioma with admixed gray matter can be difficult, perhaps accounting for some "gangliogliomas" that ultimately show aggressive behavior. In this multi-institutional study, 98 cases originally diagnosed as ganglioglioma were analyzed for IDH1 mutations, 86 of which had follow-up data available. Eight cases (8.2%) were positive for R132H IDH1 mutations; six had silent IDH2 mutations and two had nonsense IDH2 mutations. The presence of mutant IDH1 in gangliogliomas correlated with a greater risk of recurrence (P=0.0007) and malignant transformation and/or death (P<0.0001) compared with tumors that were IDH1 wild type. Furthermore, the age of patients with IDH1-mutant gangliogliomas was higher than those without mutations (25.5 vs. 46.1 years, P=0.0033). IDH1/2 testing of tumors suspected of being gangliogliomas may therefore be advisable, particularly in the adult population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.